Skip to main content

Advertisement

SpringerLink
Log in

Zusatz von Cetuximab zur primären Radiochemotherapie von Ösophaguskarzinomen verursacht schlechteres Gesamtüberleben

Use of cetuximab with definitive chemoradiotherapy for esophageal cancer results in decreased overall survival

  • Literatur kommentiert
  • Published:
Strahlentherapie und Onkologie Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Crosby T, Hurt CN, Falk S et al (2013) Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. Lancet Oncol 14:627–637

    Article  CAS  PubMed  Google Scholar 

  2. Baumann M, Krause M (2004) Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results. Radiother Oncol 72:257–266

    Article  CAS  PubMed  Google Scholar 

  3. Bonner JA, Harari PM, Giralt J et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567–578

    Article  CAS  PubMed  Google Scholar 

  4. Safran H, Suntharalingam M, Dipetrillo T et al (2008) Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity. Int J Radiat Oncol Biol Phys 70:391–395

    Article  CAS  PubMed  Google Scholar 

  5. Ruhstaller T, Pless M, Dietrich D et al (2011) Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06). J Clin Oncol 29:626–631

    Article  CAS  PubMed  Google Scholar 

  6. Hurt CN, Nixon LS, Griffiths GO et al (2011) SCOPE1: a randomised phase II/III multicentre clinical trial of definitive chemoradiation, with or without cetuximab, in carcinoma of the oesophagus. BMC Cancer 11:466

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. Wang KL, Wu TT, Choi IS et al (2007) Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Cancer 109:658–667

    Article  CAS  PubMed  Google Scholar 

  8. Chen Y, Wu X, Bu S et al (2012) Promising outcomes of definitive chemoradiation and cetuximab for patients with esophageal squamous cell carcinoma. Cancer Sci 103:1979–1984

    Article  CAS  PubMed  Google Scholar 

  9. Okines AF, Gonzalez de Castro D, Cunningham D et al (2013) Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trials. Eur J Cancer. doi: 10.1016/j.ejca.2013.02.007. [Epub ahead of print]

  10. Okines AF, Ashley SE, Cunningham D et al (2010) Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial. J Clin Oncol 28:3945–3950

    Article  CAS  PubMed  Google Scholar 

Download references

Einhaltung ethischer Richtlinien

Interessenkonflikt. N.H. Nicolay und K. Herfarth geben an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Klinik für Radioonkologie und Strahlentherapie, Universitätsklinikum Heidelberg, Neuenheimer Feld 400, 69120, Heidelberg, Deutschland

    N.H. Nicolay &  K. Herfarth

Authors
  1. N.H. Nicolay
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. Herfarth
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to N.H. Nicolay or K. Herfarth.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nicolay, N., Herfarth, K. Zusatz von Cetuximab zur primären Radiochemotherapie von Ösophaguskarzinomen verursacht schlechteres Gesamtüberleben. Strahlenther Onkol 190, 233–234 (2014). https://doi.org/10.1007/s00066-013-0523-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00066-013-0523-y

Search

Navigation